Acromegaly clinical trials
The registry lists 202 studies for Acromegaly across more than 10 countries. 19 are recruiting or about to start. 183 of them are mainly about Acromegaly (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-03.
Get an email when these change. Save the Acromegaly studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Ipsen (34) · Novartis Pharmaceuticals (15) · Cedars-Sinai Medical Center (10) · University of Aarhus (9) · Pfizer (7) · Crinetics Pharmaceuticals Inc. (5) · Federico II University (5) · Massachusetts General Hospital (4)
What is being tested here
Drugs under test in Acromegaly studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Dec 2026Long Term Outcome Study in Patients With Pituitary Disorders · University of Alberta
- Apr 2027A Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy Volunteers · Nanjing Chia-tai Tianqing Pharmaceutical
- Aug 2027A Study to Evaluate MAR002 for Acromegaly · Marea Therapeutics
Who these studies take
Of the 14 Acromegaly studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger. 2 (14%) take children under 18. 0 (0%) are for women only and 1 (7%) for men only; 4 (29%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (14%) | 2 (14%) |
| 18 | 12 (86%) | 13 (93%) |
| 30 | 13 (93%) | 14 (100%) |
| 40 | 13 (93%) | 14 (100%) |
| 50 | 13 (93%) | 13 (93%) |
| 65 | 12 (86%) | 12 (86%) |
| 75 | 11 (79%) | 11 (79%) |
| 85 | 8 (57%) | 8 (57%) |
Across all 202 studies, recruiting or not: 28% stop at 75 or younger and 9% at 65; 5% take children; 1% are for women only and 2% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Acromegaly studies take
Of 26 observational studies under Acromegaly, half reached primary completion within 85 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Observational | 85 mo38–263 · 26 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Stopped1
- Hypoproteic Diet in AcromegalySuspendedOct 29, 2026NCT05298891
Newly registered1
- A Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy VolunteersNov 2, 2026NCT07909837
Studies
Recruiting first, then most recently updated. Showing 50 of 202. Browse all 202 → or search them.
- A Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy VolunteersRecruitingNCT07909837Phase 11 country
- An Observational Study of Octreotide Subcutaneous Depot in Patients With AcromegalyRecruitingNCT075835632 countries
- A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin AnalogsRecruitingNCT06930625Phase 321 countries
- An Investigation of Pituitary Tumors and Related Hypothalmic DisordersRecruitingNCT000015951 country
- PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary TumoursNot yet recruitingNCT07813351Phase 3
- A Study to Evaluate MAR002 for AcromegalyRecruitingNCT07641179Phase 21 country
- Direct Versus Video Laryngoscopy in Patients With AcromegalyNot yet recruitingNCT07659912
- A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With AcromegalyNot yet recruitingNCT07623824Phase 3
- Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPARecruitingNCT004611881 country
- Study of MAR002 in Healthy MenRecruitingNCT07195175Phase 11 country
- Ultrasound in Predicting Difficult Intubation in Acromegaly PatientsNot yet recruitingNCT073063251 country
- Effects of Pasireotide Lar Therapy on Bone MetabolismRecruitingNCT071799261 country
- Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional StudyRecruitingNCT059647121 country
- The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In AcromegalyRecruitingNCT065973831 country
- Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess.RecruitingNCT063446501 country
- Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical ModelsNot yet recruitingNCT06326853
- Diet in the Management of AcromegalyRecruitingNCT05401084Not applicable1 country
- The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness ResearchRecruitingNCT031580901 country
- Developing a Simple Recognition System of AcromegalyRecruitingNCT030420261 country
- Hypoproteic Diet in AcromegalySuspendedNCT05298891Not applicable1 country
- A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)CompletedNCT07663318Phase 11 country
- A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With AcromegalyCompletedNCT07814651Phase 21 country
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyCompletedNCT04076462Phase 310 countries
- ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With AcromegalyTerminatedNCT07037420Phase 24 countries
- A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)TerminatedNCT04261712Phase 27 countries
- Korean Regulatory Post Marketing Surveillance for SomavertCompletedNCT051311001 country
- A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)TerminatedNCT05192382Phase 315 countries
- A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of AcromegalyTerminatedNCT04837040Phase 314 countries
- ACRODAT Prospective Evaluation StudyCompletedNCT043498391 country
- Peri-operative Dynamics of the Growth Hormone Axis in Subjects With AcromegalyCompletedNCT009216091 country
- Long Term Outcome Study in Patients With Pituitary DisordersActive, not recruitingNCT03665064
- A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyCompletedNCT04125836Phase 311 countries
- Reproducibility and Utility of OGTT in AcromegalyCompletedNCT04066569Not applicable1 country
- A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)TerminatedNCT05364944Phase 18 countries
- Ketogenic vs. Mediterranean Diet on Metabolic and Hormonal Parameters in Patients With Active AcromegalyCompletedNCT07100587Not applicable1 country
- A Prospective Study of Outcome After Therapy for AcromegalyCompletedNCT018098081 country
- A Phase 1 Study of TE-8214 Solution in Healthy VolunteersCompletedNCT06372652Phase 11 country
- Treatment Patterns and Treatment Outcomes for AcromegalyCompletedNCT030435861 country
- A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)CompletedNCT03792555Phase 28 countries
- An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)CompletedNCT03789656Phase 212 countries
- Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin AnalogsWithdrawnNCT013710451 country
- Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in ChinaCompletedNCT054318031 country
- PegvisOMant and the Immune SystEm (PROMISE)CompletedNCT050693241 country
- A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and AcromegalyCompletedNCT062538971 country
- A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With AcromegalyCompletedNCT04522180Phase 210 countries
- Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesCompletedNCT01794793Phase 428 countries
- Acromegaly Resistant to Conventional Dose of First Generation Somatostatin LigandsCompletedNCT066076661 country
- Effects of Sandostatin LAR® in AcromegalyCompletedNCT01424241Phase 41 country
- Acromegaly: Balance, Falls and Fracture RiskCompletedNCT057528251 country
- Dynamic Hormone Diagnostics in Endocrine DiseaseCompletedNCT029343994 countries